Raven Ladner, MD
Family Medicine · Byram, MSNPI 1740549781
Payments from drug & device makers
Across 206 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$592
- Pfizer$446
- Lilly USA, LLC$390
- GSK$278
- Amgen$235
- Boehringer Ingelheim$198
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,509100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $592 |
| Pfizer | 28 | $446 |
| Lilly USA, LLC | 25 | $390 |
| GSK | 17 | $278 |
| Amgen | 16 | $235 |
| Boehringer Ingelheim | 12 | $198 |
| AstraZeneca | 11 | $183 |
| Johnson & Johnson | 6 | $163 |
| Sunovion Pharmaceuticals Inc. | 6 | $111 |
| Novo Nordisk | 7 | $109 |
| Novartis | 7 | $107 |
| Abbott | 5 | $95 |
| Amarin Pharma, Inc. | 4 | $78 |
| Scilex Pharmaceuticals Inc. | 1 | $73 |
| Merck | 4 | $61 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Astellas Pharma US Inc | 2 | $47 |
| Sanofi | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 3 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| CSL Behring | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$103
How this compares
$3,515 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 116 | $151,120 |
| MounjaroTirzepatide | 128 | $144,759 |
| OzempicSemaglutide | 76 | $104,616 |
| EliquisApixaban | 79 | $95,423 |
| TrulicityDulaglutide | 42 | $70,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $29,528 |
| LinzessLinaclotide | 17 | $26,772 |
| JanuviaSitagliptin Phosphate | 34 | $22,768 |
| MyrbetriqMirabegron | 30 | $18,870 |
| XareltoRivaroxaban | 13 | $16,874 |
| FarxigaDapagliflozin Propanediol | 13 | $16,105 |
| VraylarCariprazine Hcl | 11 | $15,319 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,707 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $9,108 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $390 | $215,134170 claims |
| Boehringer IngelheimJardiance | $198 | $151,120116 claims |
| Novo NordiskOzempic | $109 | $104,61676 claims |
| PfizerEliquis | $446 | $95,42379 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $278 | $46,55369 claims |
| AbbVieLinzess, Vraylar, Synthroid | $592 | $43,53339 claims |
| MerckJanuvia | $61 | $22,76834 claims |
| AstraZenecaFarxiga, Symbicort | $183 | $22,67935 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $18,87030 claims |
| Johnson & JohnsonXarelto | $163 | $16,87413 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $52 | $6,55713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Byram
- Scott DavisByram$11K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.